Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...
JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...
Deep in our cells, a wide range of processes are occurring constantly. These cellular processes rely on enzymes to act as catalysts and set off a series of molecular interactions. There are still many ...
Understanding the connection between behavior and brain cell activity is a major goal of neuroscience. To make progress, neuroscientists often choose simple, transparent lab animals because it's ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...
Neuromuscular diseases comprise a heterogeneous group of disorders characterized by progressive impairment of muscle function resulting from defects in ...